Video

Identifying Transplant Candidates in ALL

For High-Definition, Click

Objective parameters, such as performance status and comorbidity score, may be used to determine the eligibility of adult patients who have acute leukemia for stem cell transplant. Mark R. Litzow, MD, states that he considers any patient with high-risk, Philadelphia chromosome negative [Ph(-)] acute lymphoblastic leukemia (ALL) to be a candidate for transplant. Litzow comments that it is becoming increasingly difficult to determine the best candidate for transplant, but that it is still important to consider comorbidities, disease status, and donor availability.

Dan Douer, MD, notes that most clinical studies have demonstrated that allogeneic transplants are superior to autologous transplants in ALL; in fact, autologous transplants are not considered in this disease state. Jeffrey Lancet, MD, states that beyond first remission, allogeneic transplant offers the only realistic chance of cure and should be considered in this particular setting.

Related Videos
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.